GLAXOSMITHKLINE PHARMACEUTICALS – Darkhorsestocks

Reading Time: 5 minutes


DARKHORSESTOCKS has always picked up contrarian ideas. Now when entire Pharma sector is in Limelight those People who had participated in payments this year are the ones who have been strictly following and are ripping benefits of the ideas presented here. In past 1 – 1.5 year following Pharma companies have been suggested and here are the gains each of those companies have made.

Apart from the recents suggestions of Bajaj Group and Cholamandalam there are no other finance companies suggested when no portfolio of Mutual funds, Pms or of an individual Investors existed without Banks such as Kotak Bank , Hdfc Bank , Bajaj Finserv etc yet majority of the companies suggested here have been able to deliver phenomenal returns.

So what’s next?

For this week we would suggest you to explore Glaxosmithkline Pharmaceuticals which was suggested previously. More Information can be found from the link below.

Meanwhile also check the short web series effects of COVID-19 on the world economy because this is going to be extremely useful for all the individuals who are interested in stock market. The things taught are wonderful and extremely important from an investors perspective.

Youtube-: Effects of COVID-19 on the world Economy

GlaxoSmithKline Pharmaceuticals -:

GlaxoSmithKline Pharmaceutical a 95 years old Indian Subsidiary, 100% debt free company is a part of ClaimSmithKline plc (GSK) a British multinational pharmaceutical company headquartered in Brentford, London.

It is one of the oldest pharmaceuticals companies in India. Its product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectious, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases. 

It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzac, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer and others. The company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company develops a range of prescription medicines, vaccines and consumer healthcare products. 

Also Read on FinMedium:  Indraprastha Gas vs MGL - 4 Points Analysis

The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It delivers over two million vaccine doses per day to people living in over 160 countries 

Parent History-: 

GlaxoSmithKline plc (GSK) is a British multinational Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world’s sixth largest pharmaceutical company as of 2015, after Pfizer, Novartis, Merck, Hoffmann-La Roche and Sanofi. 

The parent company completed the acquisition of TESARO, Inc. an oncology-focused company in January 2019. The transaction, which was announced in December 2018, significantly strengthens its oncology pipeline and brings new scientific capabilities and expertise that will increase the pace and scale at which it can help patients living with cancer.

One of the highlights of FY 2019 was the launch of Nucala® (Mepolizumab), a humanised monoclonal antibody which is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients. 

The company is forging ahead on the innovation front, with the recent launch of Nucala, a biologic for severe refractory eosinophilic asthma in adults. 

India has around 30 million asthma patients and Nucala will bring significant relief to those among them who suffer from severe eosinophilic asthma. In addition, this breakthrough innovation will also strengthen the respiratory portfolio to better serve the patients. The commercial and medical teams are actively engaging with pulmonologists in the country to disseminate the robust data on Nucala. 

With an investment of over Rs 1000 crore, its upcoming manufacturing facility at Vemgal, Karnataka, will be the first grecnfield pharmaceutical manufacturing site that GSK has built globally over the past ten years. It is also the first facility designed for the new GSK Production Systems (GPS), whereby it will deliver the concepts of zero accidents, zero defects and zero waste. 

Also Read on FinMedium:  Can Castrol India Survive The Electric Vehicle Revolution?

To put it in perspective, the company’s March 2019 gross block on consolidated basis is just Rs 561 crore . Thus once the new site is commissioned gross block is expected to almost triple. 

Merck and Pfizer, of the United States, Sanofi, in France, and the London-listed Glaxosmithkline. Between them, they account for about 85 per cent of a worldwide vaccines market worth $35 billion, according to analysts at Bernstein. 

Glaxo is the biggest of them all, based on the percentage of its revenues, at 21 per cent, that come from such treatments — and it might be tempting to conclude that Glaxo’s vaccines business is looking a little more valuable.

Recently the drug giant GlaxoSmithKline said that it will collaborate with Vir  Biotechnology on experimental treatments and potentially, vaccines against the novel coronavirus. As part of the deal, GlaxoSmithKline will invest $250 million in the San Francisco startup at a 10% premium to the company’s closing share price on March 27. 

The agreement includes Vir’s lead drugs against the novel coronavirus, which are monoclonal antibodies that could enter efficacy studies in humans in three to five months. The deal includes an early effort to use CRISPR, the gene-editing technology, to identify medicines that might help the immune system fight off viruses. The collaboration also encompasses a long-term project to develop a vaccine that might prevent infection not only with the virus, called SARS-CoV-2, but related viruses that could cause problems in the future.

FINANCIAL HIGHLIGHTS-: 

FY 2019 consolidated results. Consolidated sales grew 8% to Rs 3128.12 crone for FY 2019. OPM improved 170 basis points to 19.2% which saw OP go up 19% to Rs 600.79 crorc. Over the past the topline growth of the company has remained flat but going forward we expect it to imporove Significantly 

Also Read on FinMedium:  Intelsense Capital Blog: Weekend Reading

Company has cash and equivalents of about 1170 cr as of march 2019 which puts it as a great advantage to spend on better R&D as compared to other companies struggling to manage working capital. Apart from the company does not have any debt where as the reserves stand at 1900Cr Rs. 

GlaxoSmithKline Pharmaceuticals was previously suggested at 1200 Rs since then the stock has delivered almost 35% returns before falling to current levels.

Click here to go to home page.



Source link

Disclaimer: The opinions expressed in this publication are those of the authors. They do not purport to reflect the opinions or views of the FinMedium or its members. The presentation of material therein does not imply the expression of any opinion whatsoever on the part of the FinMedium concerning the legal status of any company, country, area, or territory or of its authorities. For more info. please read our ToU & Privacy Policy here. If you have any concerns regarding this post, please reach out to us at finmedium@gmail.com

Every Wednesday and Saturday, we send Info-Graphic and FinMedium Weekly Digest newsletters to our 25000+ Subscribers.

Join Them Now!


Dark Horse Stocks

Dark Horse Stocks

DHS aims to reach a wider audience by providing them with access to the data. Thereby helping them analyze financial reports and make their own investment decisions.
Please Share Now :)